InvestorsObserver
×
News Home

Should Biotechnology Stock Nkarta Inc (NKTX) Be in Your Portfolio Thursday?

Thursday, December 08, 2022 12:57 PM | InvestorsObserver Analysts

Mentioned in this article

Should Biotechnology Stock Nkarta Inc (NKTX) Be in Your Portfolio Thursday?

A rating of 35 puts Nkarta Inc (NKTX) near the middle of the Biotechnology industry according to InvestorsObserver. Nkarta Inc's score of 35 means it scores higher than 35% of stocks in the industry. Nkarta Inc also received an overall rating of 38, putting it above 38% of all stocks. Biotechnology is ranked 58 out of the 148 industries.

Overall Score - 38
NKTX has an Overall Score of 38. Find out what this means to you and get the rest of the rankings on NKTX!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Nkarta Inc Stock Today?

Nkarta Inc (NKTX) stock is down -1.03% while the S&P 500 is higher by 0.63% as of 12:54 PM on Thursday, Dec 8. NKTX has fallen -$0.08 from the previous closing price of $7.76 on volume of 240,625 shares. Over the past year the S&P 500 is down -15.79% while NKTX has fallen -51.91%. NKTX lost -$2.68 per share the over the last 12 months. Click Here to get the full Stock Report for Nkarta Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App